PharmaNet Development Group and Analytica International, a wholly owned subsidiary of Accentia Biopharmaceuticals, have entered into a strategic alliance that will allow the companies to provide a broader range of clinical development and commercialization services to their clients.

PharmaNet provides clinical development services including early and late stage trials and related services. Analytica is a healthcare research consultancy that provides outcomes research, pricing and reimbursement analysis for global pharmaceutical, biotechnology, and medical device companies.

“Analytica International’s outcomes research will enhance PharmaNet’s clinical trial services offering when health outcomes are part of the sponsor’s large scale, Phase III-IV trial protocol,” commented Jeffrey P. McMullen, president and chief executive officer, PharmaNet Development Group, Inc.

“Our global biopharmaceutical clientele are looking for an integrated approach to designing and implementing clinical trials that incorporate outcomes research endpoints to maximize the value proposition of their products,” commented Dr. John Doyle, president and chief operating officer, Analytica International, Inc.